The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to witness a noteworthy CAGR of 6.1% over the forecast period. Rising prevalence of primary and acquired immunodeficiency diseases such as congenital AIDS and hypogammaglobulinemia is a major growth driver of this market.

Rising cases of primary immune deficiency diseases are expected to drive the demand for fast, accurate, and safe treatment options, thereby boosting the market growth. Other IVIG applications, such as neurological disorders, organ transplantation, peripheral neuropathies, and Alzheimer’s disease, also provide a lucrative growth opportunity to the market players. Thus, growing cases of aforementioned diseases are also expected to increase the penetration of IVIG in the near future.

Market participants are actively involved in R&D for the development of innovative drugs and discovering new therapeutic areas for the existing drugs. For instance, in 2017, Kedrion Biopharma, Inc. and Kamada Ltd. received approval from the U.S. FDA for their new product KEDRAB. Industry players are also involved in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio.

For example, in June 2018, Shire plc received approval from the U.S. FDA for its new plasma manufacturing facility near Covington, Georgia, thereby increasing the company’s production capacity. The expected product approvals in the coming years are anticipated to help fuel the market growth.

Further key findings from the study suggest:

Hypogammaglobulinemia segment held the substantial share of around 20.0% based on application in 2017, owing to rising adoption of IgG intravenous and subcutaneous replacement therapies

Kawasaki diseases segment is expected to grow lucratively at a CAGR of 9.2% over the forecast period owing to increasing disease prevalence in U.S.

IVIG held the largest share of the route of administration segment of U.S. IG market owing to their high adoption in the treatment of immune deficiency diseases

Subcutaneous immunoglobulin is expected to witness the fastest CAGR of over 11% during the forecast period due to its benefits, such as shorter administration duration and fewer needle punctures

Hospital pharmacy held the largest share in 2017 owing to the presence of a large number of hospital pharmacies and easy availability of products in the hospitals.